title: [Effectiveness of antiviral treatment of patients with chronic hepatitis C (a Polish multicenter study)].
abstract: Interferon alpha (INF) is routine treatment in patients with chronic hepatitis C. Many controlled investigations were evaluated to establish the optimal schedule of treatment with sustained virological and biochemical response. Recently, multicentre meta-analyses suggest that combination therapy (INF + Ribavirin) was more effective than treatment with interferon alone. The aim of this study was to compare the efficacy of four schedules of antiviral treatment in 445 patients with chronic hepatitis C. Combination therapy (INF + Ribavirin) given for 6 mo. and monotherapy (INF) for 18 mo. were more effective than interferon alone given for 6 mo. Treatment with INF alone for 6 mo. was demonstrated to be insufficient.
authors.affiliation: Klinika Chorób Zakaźnych Instytutu Mikrobiologii i Chorób Zakaźnych AM w Poznaniu.
authors.forename: J
authors.initials: J
authors.lastname: Juszczyk
authors.forename: B
authors.initials: B
authors.lastname: Bolewska
authors.forename: J
authors.initials: J
authors.lastname: Flieger
authors.forename: K
authors.initials: K
authors.lastname: Swietek
authors.forename: B
authors.initials: B
authors.lastname: Adamek
authors.forename: M
authors.initials: M
authors.lastname: Biskupska-Karasińska
authors.forename: A P
authors.initials: AP
authors.lastname: Dziambor
authors.forename: A
authors.initials: A
authors.lastname: Boroń-Kaczmarska
authors.forename: M
authors.initials: M
authors.lastname: Wawrzynowicz-Syczewska
authors.forename: J
authors.initials: J
authors.lastname: Cianciara
authors.forename: J
authors.initials: J
authors.lastname: Kozłowska
authors.forename: J
authors.initials: J
authors.lastname: Daniluk
authors.forename: M
authors.initials: M
authors.lastname: Słomka
authors.forename: M
authors.initials: M
authors.lastname: Dudziak
authors.forename: P
authors.initials: P
authors.lastname: Zaborowski
authors.forename: A
authors.initials: A
authors.lastname: Gładysz
authors.forename: P
authors.initials: P
authors.lastname: Piszko
authors.forename: Z
authors.initials: Z
authors.lastname: Gonciarz
authors.forename: W
authors.initials: W
authors.lastname: Mazur
authors.forename: M
authors.initials: M
authors.lastname: Machniak
authors.forename: W
authors.initials: W
authors.lastname: Kryczka
authors.forename: D
authors.initials: D
authors.lastname: Zarebska-Michaluk
authors.forename: H
authors.initials: H
authors.lastname: Trocha
authors.forename: K
authors.initials: K
authors.lastname: Witczak-Malinowska
authors.forename: E
authors.initials: E
authors.lastname: Lakomy
authors.forename: J
authors.initials: J
authors.lastname: Kuydowicz
authors.forename: A
authors.initials: A
authors.lastname: Niwicka-Michałowska
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D011044:Poland / Q000453:epidemiology; D012254:Ribavirin / Q000008:administration & dosage* / Q000009:adverse effects; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin
vernacular_title: Efektywność leczenia przeciwwirusowego przewlekłego zapalenia watroby typu C (wieloośrodkowe badania pòlskie).